Immunomedics Inc. (NASDAQ:IMMU) shares traded up 2.5% during trading on Thursday . The stock traded as high as $2.87 and last traded at $2.83, with a volume of 272,832 shares traded. The stock had previously closed at $2.76.

Several research analysts have commented on the stock. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Immunomedics in a research note on Tuesday, May 24th. Jefferies Group reaffirmed a “buy” rating and set a $5.00 price objective on shares of Immunomedics in a research note on Monday, June 6th. Finally, Zacks Investment Research raised shares of Immunomedics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 6th.

The firm has a 50 day moving average of $2.66 and a 200-day moving average of $2.89. The firm’s market capitalization is $264.59 million.

Immunomedics (NASDAQ:IMMU) last announced its earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.06. Analysts predict that Immunomedics Inc. will post ($0.47) EPS for the current year.

In other news, Chairman David M. Goldenberg sold 12,300 shares of the company’s stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $3.98, for a total transaction of $48,954.00. Following the completion of the transaction, the chairman now directly owns 2,602,063 shares of the company’s stock, valued at approximately $10,356,210.74. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Cynthia L. Goldenberg sold 371,990 shares of the company’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $3.03, for a total value of $1,127,129.70. Following the transaction, the chief executive officer now directly owns 650,396 shares of the company’s stock, valued at $1,970,699.88. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Immunomedics stock. Marshall Wace LLP bought a new stake in Immunomedics Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 857,062 shares of the biopharmaceutical company’s stock, valued at approximately $2,631,000. Marshall Wace LLP owned 0.90% of Immunomedics as of its most recent SEC filing.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.